Summit Securities Group’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
Summit Securities Group's MDGL Position: Q3 2026 in Review
Summit Securities Group sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 148 shares — an estimated $79.5K sold.
Summit Securities Group first reported a position in MDGL in Q2 2013 and held it in 4 quarters. The position peaked at $79.5K in Q2 2026. 407 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- Summit Securities Group reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Summit Securities Group sold 148 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $79.5K.
- Summit Securities Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 4 quarters.
- Summit Securities Group's Madrigal Pharmaceuticals position peaked at $79.5K in Q2 2026.
- 407 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.